Information Provided By:
Fly News Breaks for January 7, 2019
Jan 7, 2019 | 15:26 EDT
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $25 price target on Arrowhead Pharmaceuticals after the company announced it dosed the first patient in Phase I ARO-ANG3 study and will commence Phase I dosing of ARO-APOC3 upon CTA approval. The analyst also sees at least two additional TRiM RNAi candidates entering the clinic in 2019, including ARO-ENaC and ARO-HIF2. Most important, Arrowhead will initiate a potentially registrational Phase II/III study for ARO-AAT in Q1 of 2019.
News For ARWR From the Last 2 Days
There are no results for your query ARWR